Testosterone Science

Media Watch

US Examines Testosterone Therapy for Women

Specific Claim Evaluated

Evidence supports testosterone only for postmenopausal women with hypoactive sexual desire disorder, data are insufficient for mood, cognition or well-being, and oral testosterone is not recommended because of cholesterol effects.

Primary Research Supporting or Contradicting the Claim

The consensus statement supports testosterone only for postmenopausal hypoactive sexual desire disorder and advises against oral formulations because of adverse lipid effects (Davis et al., 2019; Islam et al., 2019).

Corrected Evidence-Based Interpretation

The report is correct.

Rationale for Grade

The article presents differing views from the workshop, states the regulatory history and reports the evidence base accurately.

References

  1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
    Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."
  2. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. PMID
    Supporting excerpt: "Testosterone is effective for postmenopausal women with low sexual desire causing distress"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.